Other Publication Details
Mandatory Fields
Reviews
Giles, FJ,O'Dwyer, M,Swords, R
2009
October
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Published
1
Optional Fields
CML imatinib nilotinib dasatinib TKI BCR-ABL CHRONIC MYELOGENOUS LEUKEMIA PHASE CML-CP PATIENTS RECEIVING IMATINIB LYN-DEFICIENT MICE BCR-ABL MUTATIONS CYTOGENETIC RESPONSES BLAST CRISIS IN-VIVO SELECTIVE INHIBITOR CLINICAL RESISTANCE
Tyrosine kinase inhibitors have revolutionized the treatment of chronic myeloid leukemia (CML), offering patients several targeted therapeutic options that provide the possibility of sustained remissions and prolonged survival. With the availability of imatinib, nilotinib and dasatinib, physicians must weigh the efficacy and safety profile of each agent when choosing the best therapeutic option for individual patients. Each agent targets tyrosine kinases within the cell uniquely to cause the desired antiproliferative effect. In addition to inhibiting the BCR-ABL kinase, imatinib and nilotinib target the same array of other tyrosine kinases, including c-KIT and platelet-derived growth factor receptor (PDGFR), albeit with differing potencies. While targeting BCR-ABL with the highest potency among approved agents in CML, dasatinib also targets a broad array of off-target kinases, including SRC family members, PDGFR and EPHB4. The differences in kinase inhibition profiles among these agents in vitro probably account for the differing clinical safety profiles of these agents. This paper reviews the various kinases inhibited by imatinib, nilotinib and dasatinib, and describes the potential impact of kinase inhibition on the efficacy and safety of each agent. Leukemia (2009) 23, 1698-1707; doi: 10.1038/leu.2009.111; published online 28 May 2009
1698
1707
DOI 10.1038/leu.2009.111
Grant Details
Publication Themes